Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 344 followers
Latest posts
Last updated about 1 hour ago
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
about 1 hour ago
Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum...
Inflammation biotech Electra charges up with $350M from upsized IPO
about 1 hour ago
Electra Therapeutics is the latest biotech to overshoot its own IPO expectations...
DPHARM: How to address the clinical trial enrollment crisis?
about 12 hours ago
Clinical trials are facing an enrollment crisis. Around 80% of trials don’t...
Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
about 14 hours ago
A new biotech has sprung out of stealth with a bold vision...
Rare EGFR mutation increases lung cancer risk 62 times in never smokers
about 15 hours ago
A rare inherited germline mutation was found to increase risk for lung...
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
about 19 hours ago
After a failed merger that led to massive layoffs and a lawsuit...
North Immunology goes public via reverse merger as eczema drug heads toward clinic
about 20 hours ago
North Immunology has decided its path to taking an atopic dermatitis drug...
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
about 21 hours ago
Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker...
Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
about 21 hours ago
Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000...
SK pens $315M pact with fellow South Korean company for Parkinson’s prospect
about 21 hours ago
SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its...
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
about 22 hours ago
Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish...
Longeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’
about 23 hours ago
A phase 2b study of Longeveron’s stem cell therapy in a pediatric...